Patent application number | Description | Published |
20080213323 | Use of active principles which are capable of enhancing the content of ceramides, as protective agent for delicate lips - The present invention relates to the field of preventive and/or curative protection of delicate lips. | 09-04-2008 |
20080215610 | Methods involving artificial intelligence - One aspect of the present invention relates to methods of generating a profile data set. In an exemplary embodiment, data is accessed and the accessed data is processed using a dynamic cluster method, mobile center method, and/or a k-means algorithm, each using neighborhood data. Other aspects relate to methods of generating a diagnosis, advice, and/or other information. Further aspects relate to dynamic surveying and systems. | 09-04-2008 |
20090208958 | METHODS AND KITS FOR DETECTING SINGLE NUCLEOTIDE POLYMORPHISMS OF CHROMOSOME IMPLICATED IN PREMATURE CANITIES - Methods and kits for diagnosing a predisposition to premature canities in an individual are disclosed. A method for diagnosing a predisposition to premature canities in an individual comprises detecting at least one SNP marker of the human chromosome 9, selected from the group consisting of rs306534, rs3739902, rs575916, and rs365297. A kit for diagnosing a predisposition to premature canities comprises a means for detecting in a sample of human genetic material, the allele of a SNP marker of the human chromosome 9 selected from the markers rs306534, rs3739902, rs575916 and rs365297; and a positive or negative control. | 08-20-2009 |
20090239312 | Chromosome 6 and 9 Genes Involved in Premature Canities - The invention provides a cosmetic or therapeutic method for combating canities and/or stimulating natural pigmentation and/or treating a pigmentation disorder comprising administering at least one polynucleotide fragment comprising 18 consecutive nucleotides, the sequence of which corresponds to all or part of a gene on human chromosome 9 selected from the group consisting of the FREQ, NT_030046.18, NT_030046.17, GTF3C5, CEL, CELL, FS, ABO, BARBLI, DDX31, GTF3C4 and Q96MA6 genes, or the sequence of which corresponds to all or part of a gene on human chromosome 6 selected from the HLAG, NT_007592.445, NT_007592.446, NT_007592.506, NT_007592.507, NT_007592.508, HSPA1 B, G8, NEU1, NG22, BAT8, HLA-DMB, HLA-DMA, BRD2, HLA-DQA1, HLA-DQA2, NT_007592.588, GRM4, RNF23, FLJ22638, NT_007592.459 and NT_007592.457 genes, and diagnostic methods employing same. | 09-24-2009 |
20090275033 | Uses of BNIPXL-Beta in premature canities - The present invention concerns the use of a polypeptide comprising a sequence having at least 90% identity with all or part of BNIPXLβ, for cosmetic or therapeutic applications, in the treatment or prevention of premature canities in humans, said portion comprising at least 30 amino acids, as well as the use, for the same purpose, of a molecule comprising a RNAi sequence having at least 90% identity with all or part of the cDNA sequence of BNIPXLβ, said part comprising at least 18 nucleotides. | 11-05-2009 |
20140044799 | MOLECULAR SIGNATURE OF CUTANEOUS PIGMENTARY SPOTS, ASSOCIATED WITH THE ORGANIZATION OF THE EXTRACELLULAR MATRIX - The present invention concerns a molecular signature of cutaneous pigmentary spots, comprising the genes MXRA5, LYZ, CTSL2, PLAU, TIMP1, EFEMP1, ECM1, ASPN, HS3ST6, PAPLN, CHSY1 and FLRT2, and various applications of this signature. In particular, the invention concerns a method for characterizing a known or suspected pigmentary spot in a human being, comprising comparing the levels of expression in skin samples obtained from said spot and from adjacent undamaged skin, of at least one dermal gene linked to matrix remodelling or to its extracellular proteoglycan and glycoprotein components, selected from the list constituted by the genes MXRA5, LYZ, CTSL2, PLAU, TIMP1, EFEMP1, ECM1, ASPN, HS3ST6, PAPLN, CHSY1 and FLRT2. The invention also concerns methods for evaluating the efficacy of a pigmentary spot treatment, cosmetic and therapeutic methods for the treatment of pigmentary spots, and various modulators for said genes, and their use. | 02-13-2014 |
20150307940 | MOLECULAR SIGNATURE OF CUTANEOUS PIGMENTARY SPOTS, ASSOCIATED WITH THE EXTRACELLULAR MATRIX - The present invention concerns a molecular signature of cutaneous pigmentary spots, comprising the genes TGFBR2, TGFBI, BMP2, SMAD3, THBS2, TGFBR3, SEMA5A, SMAD7, SOSTDC1, FRAS1, LEPREL1, MATN2, DST, PLOD2, ITGA2, COL6A3, CRTAP, LAMC1, LAMB3, LAMA3, ITGAV, ITGB1 and ACTN1, and various applications of this signature. In particular, the invention concerns a method for characterizing a known or suspected pigmentary spot in a human being, comprising comparing the levels of expression in skin samples obtained from said spot and from adjacent undamaged skin, of at least one dermal gene linked to the extracellular matrix selected from the list constituted by the genes TGFBR2, TGFBI, BMP2, SMAD3, THBS2, TGFBR3, SEMA5A, SMAD7, SOSTDC1, FRAS1, LEPREL1, MATN2, DST, PLOD2, ITGA2, COL6A3, CRTAP, LAMC1, LAMB3, LAMA3, ITGAV, ITGB1 and ACTN1. The invention also concerns methods for evaluating the efficacy of a pigmentary spot treatment, cosmetic and therapeutic methods for the treatment of pigmentary spots, and various modulators for said genes, and their use. | 10-29-2015 |